Palavras-chave
tiroides
patología
Como Citar
Resumo
El diagnóstico de carcinoma papilar (CP) de tiroides se realiza, en la gran mayoría de casos, teniendo en cuenta los hallazgos histopatológicos en hematoxilina eosina, pero cuando la morfología no es clara o la variante está encapsulada, se dificulta el diagnóstico; además, algunos cambios hiperplásicos floridos pueden confundir al patólogo y llevarlo a un diagnóstico erróneo. Diferentes estudios han demostrado que el uso de marcadores de inmunohistoquímica puede llegar a ser útil en casos en que el diagnóstico se dificulta. Se revisó la expresión de CK19, CD56 y p63 en CP y en lesiones foliculares neoplásicas no papilares y no neoplásicas. Se seleccionaron 29 casos de CP, incluidas diferentes variantes y 31 casos de patología tiroidea que no correspondieran a CP. El 100 % de los CP mostró positividad fuerte y difusa para CK19, y el 88 % mostró negatividad con CD56. Solo el 64 % de todos los CP mostraron positividad focal y selectiva nuclear con p63. El 100 % de los casos de patología tiroidea no CP mostró positividad fuerte y difusa para CD56 y negatividad con CK19. Con este estudio se corrobora lo encontrado en estudios previos: el uso de CK19 y CD56 es una herramienta útil en el diagnóstico de CP cuando la morfología no es clara.
International Agency for Research on Cancer, World Health Organization. Globocan 2008: cancer incidence and mortality worldwide in 2008 [internet]. Disponible en: http://globocan.iarc.fr/.
DeLellis RA, Lloyd RV, Heits PU, Eng C, editors. World Health Organization Classification of Tumours: pathology and genetics of tumours of endocrine organs. Lyon: IARC Press; 2004.
El Demellawy DE, Nasr A, Alowami S. Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagn Pathol. 2008;3:5.
Asa SL, Cheung CC. The mind´s eye. Am J Clin Pathol. 2001;16: 635-6.
Chan JKC. Strict criteria should be applied in the diagnosis of encapsulated follicular variant of papillary thyroid carcinoma. Am J Clin Pathol. 2002;117:16-8.
Baloch ZW, LiVolsi VA. Follicular-patterned lesions of the thyroid: the bane of the pathologist. Am J Clin Pathol. 2002;117:143-50.
Lloyd RV, Erickson LA, Casey MB et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol. 2004;28:1336-40.
Hirokawa M, Carney JA, Goellner JR et al. Observer variation of encapsulated follicular lesions of the thyroid gland. Am J Surg Pathol. 2001;26(11):1508-14.
Rosai J, Kuhn E, Carcangiu ML. Pitfalls in thyroid tumour pathology. Histopathol. 2006;49:107-20.
Perez-Montiel MD, Suster S. The spectrum of histologic changes in thyroid hyperplasia: a clinicopathologic study of 300 cases. Hum Pathol. 2008;39:1080-7.
Cheung CC, Ezzat S, Freeman J, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Path. 2001;14(4):338-42.
Fisher S, Asa SL. Application of immunohistochemistry to thyroid neoplasms. Arch Pathol Lab Med. 2008;132:359-70.
Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet. 2001;357:1644-50.
Rezk S, Khan A. Role of immunohistochemistry in the diagnosis and progression of follicular epithelium-derived thyroid carcinoma. Appl Immunohistochem Mol Morphol. 2005;13(3):256-61.
Choi YL, Kim MK, Suh JW, Han J et al. Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas. J Korean Med Sci. 2005;20:853-9.
Lam KY, Lui MC, Lo CY. Cytokeratin expression profiles in thyroid carcinomas. Eur J Surg Oncol. 2001;27:631-5.
Baloch ZW, Abraham S, Roberts S, Livolsi VA. Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility. Hum Pathol. 1999;30(10):1166-70.
Sahoo S, Hoda SA, Rosai J, DeLellis RA. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution. Am J Clin Pathol. 2001;116:696-702.
Zeromski J, Bagnasco M, Paolieri F, Dworacki G. Expression of CD56 (NKH-1) differentiation antigen in human thyroid epithelium. Clin Exp Immunol. 1992;89:474-8.
Cavallaro U, Niedermeyer J, Fuxa M, Christofori G. N-CAM modulates tumorcell adhesion to matrix by inducing FGFreceptor signaling. Nature Cell Biol. 2001;3:650-7.
Prag S, Lepekhin EA, Kolkova K, Hartmann-Petersen, Kawa A, Walmod PS, Belman V, Gallagher HC. NCAM regulates cell motility. J Cell Scienc. 2002;115:283-92.
Levrero M, De Laurenzi V, Costanzo A, Sabatini S, Gong J, Wang JYJ, Mellino G. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci. 2000;113:1661-70.
Preto A, Reis-Filho JS, Ricardo S, Soares P. P63 expression in papillary and anaplastic carcinomas of the thyroid gland: lack of an oncogenetic role in tumorigenesis and progression. Pathol Res Pract. 2002;198:449-54.
Baloch ZW, LiVolsi VA. Warthin-like papillary carcinoma of the thyroid. Arch Pathol Lab Med. 2000;124:1192-5.
Urano M, Abe M, Kuroda M et al. Warthin-like tumor variant of papillary thyroid carcinoma: Case report and literature review. Pathol Interl. 2001;51:707-12.
Kim H, Myssiorek D, Heller K, Zahurullah F, Bhuiya T. Warthin-like tumor of the thyroid gland: An uncommon variant of papillary thyroid cancer. Ear, Nose Throat J. 2006;85(1):56-9.
This journal is registered under a Creative Commons Attribution 4.0 International Public License. Thus, this work may be reproduced, distributed, and publicly shared in digital format, as long as the names of the authors and Pontificia Universidad Javeriana are acknowledged. Others are allowed to quote, adapt, transform, auto-archive, republish, and create based on this material, for any purpose (even commercial ones), provided the authorship is duly acknowledged, a link to the original work is provided, and it is specified if changes have been made. Pontificia Universidad Javeriana does not hold the rights of published works and the authors are solely responsible for the contents of their works; they keep the moral, intellectual, privacy, and publicity rights.
Approving the intervention of the work (review, copy-editing, translation, layout) and the following outreach, are granted through an use license and not through an assignment of rights. This means the journal and Pontificia Universidad Javeriana cannot be held responsible for any ethical malpractice by the authors. As a consequence of the protection granted by the use license, the journal is not required to publish recantations or modify information already published, unless the errata stems from the editorial management process. Publishing contents in this journal does not generate royalties for contributors.